In order to deliver this event, we depend on corporate support. Collaboration with the pharmaceutical industry is vital for both the organizational as well as the scientific success of the program.

For industry support opportunities please contact our managing director, Mrs Alice Posthumus-Plantinga at, or call +31 6 2248 2179.


Abstract Submission Guidelines

Abstracts should contain the following four components:

- Background: a concise statement of the issue under investigation or a hypothesis;
- Materials & Methods: the experimental methods used (including the statistical analyses employed);
- Results: specific findings (promises such as “to be completed” or “to be presented” are not acceptable);
- Conclusions: a summary of findings that are supported by your results (statistical analyses used to support the conclusions, where appropriate, should be included; concluding statements such as “the results will be discussed” are not acceptable).

Please note that abstracts cannot be accepted if tables, graphs, grant acknowledgements or literature references are included. The maximum word count for the abstract body is 500 words.

Abstracts are considered official communications to the conference and will be treated confidentially. For those abstracts that are accepted, submitters agree to attend the meeting and present their abstract as scheduled.

Abstract submission

Authors can submit their abstracts electronically until 18 August 2017 by using the submission button to the right of the screen. You will be redirected to the submission website. Please follow the step-by-step directions, which will enable you to upload the abstract. To ensure your abstract retains any special characters or formatting, the abstract must be in Microsoft Word format.

Categories for abstract submission

For purposes of review and programming, abstracts are divided into topical categories. Selection of the most appropriate category is important as it determines who reviews your abstract. The Organizing Committee reserves the right to reassign your abstract to a more appropriate category.

Topics for abstract submission

Selection of the most appropriate topic is important as it determines who reviews your abstract. The Organizing Committee reserves the right to reassign your abstract to a more appropriate category.

- Pharmacokinetics and Pharmacodynamics of Approved TB Drugs
- Pharmacokinetics and Pharmacodynamics of New TB Drugs
- Population pharmacokinetics & pharmacokinetic-pharmacodynamic modeling
- Drug development and optimization: approaches & tools
- Drug-drug and drug-disease state interactions
- TB treatment in special populations

Notification of abstract dispositions

Notifications of acceptance and format of presentation (oral or poster presentation) will be e-mailed to submitting authors early September 2017. It is the responsibility of the corresponding/presenting author to inform all co-authors of the abstract’s status. Please notify the Conference Secretariat if you have not received notification by the end of September.

If an abstract is accepted, one author is required to register for the conference and present the paper as scheduled. An Abstract Submitter’s Registration Form will be sent together with the notification to be used by the attending author to apply for the regular registration fee. Guidelines for preparing your oral and/or poster presentations will be sent after your abstract has been accepted.

Abstract publication

Accepted abstracts will be published in the Abstract Book which will be distributed during the conference. Please note that the conference secretariat cannot be held responsible for any typing or language errors in the submitted abstracts as only the format of the abstracts will be changed and not the content.


Organizing Committee

The members of the Organizing Committee (OC) discuss, on a frequent basis, the scientific program of the workshop, identify interesting topics and candidate speakers and review all submitted abstracts.

Scientific Committee

The members of Scientific Committee assist the OC by providing them with suggestions for speakers and topics. In addition, members of the Scientific Committee actively participate in reviewing submitted abstracts.

Jan-Willem Alffenaar, PhD, PharmD UMCG, The Netherlands
Deron Burton
Dakshina Chilukuri, PhD FDA, USA
Véronique Dartois, PhD Rutgers, The State University of New Jersey, Newark, USA
Paolo Denti, PhD University of Cape Town, South Africa
Kelly Dooley, MD, PhD Johns Hopkins University, USA
Tawanda Gumbo, MD Baylor Institute for Immunology Research, USA
Richard Hafner, MD National Institutes of Health, USA
Scott Heysell, MD, MPH University of Virginia, USA
Anneke Hesseling, MD Desmond Tutu Tuberculosis Centre, South Africa
Russell Kempker, MD, MSc Emory University School of Medicine, USA
Steven Kern, PhD Bill & Melinda Gates Foundation, USA
Christian Lienhardt, MD, PhD WHO – Stop TB Department, Switzerland
Rovina Ruslami, MD, PhD Padjadjaran University, Indonesia
Ulrika Simonsson, PharmD, PhD Uppsala University, Sweden
Susan Swindells, MBBS University of Nebraska Medical Center, USA
Andrew Vernon, MD CDC, TBTC, USA
Robert Wallis, MD, FIDSA The Aurum Institute, South Africa

Meeting proceedings

Friday 5 May 2017 - Day 1

  Session 1: Priorities in Biomarker Development for NASH
Chairs: Veronica Miller & Arun Sanyal

Tetri, Brent 2017 120

A pathologist, a radiologist and a hepatologist walked into a bar
Brent Tetri, MD
Saint Louis University Health Sciences Center, St. Louis, MO, USA



Innovation in histological assessment of NASH
Pierre Bedossa, MD, PhD
University of Paris-Diderot, Paris, France


  Session 2: Pathways to Biomarker Qualification and Acceptance
Chair: Chris Leptak & Veronica Miller

Stein, Peter 120

View from the Top - Potential impact of 21st Century Cures Act?
Peter Stein, MD
FDA Center for Drug Evaluation and Research, Silver Spring, MD 

>Presentation (not available)


EU Perspective
Elmer Schabel, MD
European Medicines Agency, London, UK & BfArM, Bonn, Germany

>Webcast (soon available)


Collaboration in action: BEST
Chris Leptak, MD, PhD
FDA Center for Drug Evaluation and Research, Silver Spring, MD



Collaboration in action: FNIH
Roberto Calle, MD, FACE, FACP
Foundation for the National Institutes of Health (FNIH), Bethesda, MD, USA



Collaboration in action: IMI
Quentin Anstee, BSc, MBBS, PhD, MRCP(UK), FRCP
Newcastle University, Newcastle, United Kingdom


  Session 3: Circulating biomarkers
 Chairs: Sudha Shankar & Brent Tetri

Puri, Puneet (from web) 120x160

Lipidomics and Proteomics
Puneet Puri, MD
Virginia Commonwealth University, Richmond, VA, USA

>Presentation (not available)


Role of Genetic assessments
Quentin Anstee, BSc, MBBS, PhD, MRCP(UK), FRCP
Newcastle University, Newcastle, United Kingdom



Francque, Sven 2017 120

Circulating nucleic acids and combination panels
Sven Francque MD, PhD
Antwerp University Hospital, Antwerp, Belgium


  Session 4: Imaging Biomarkers
  Chairs: Quentin Anstee & Lara Dimick-Santos

MRI; what can it deliver
Claude Sirlin, MD
UC San Diego, San Diego, CA, USA



Vuppalanchi, Raj 2016 120x160

Transient elastography & other techniques
Raj Vuppalanchi, MBBS
Indiana University School of Medicine, Indianapolis, IN, USA


 #01 - Hepatic proton density fat fraction correlates with histologic measures of steatosis and is responsive to change in those measures in a multi-center nonalcoholic steatohepatitis clinical trial
Michael Middleton, USA
 #02 - A meta-analysis on repeatability of magnetic resonance elastography of liver
Suraj Serai, USA

Saturday 6 May 2017 - Day 2

  Session 5: Quantative assessment of hepatic health
 Chairs: Roberto Calle & Puneet Puri

Siddiqui, Mohammed web 120

Breath tests
Shadab Siddiqui, MD, FACP
Virginia Commonwealth University, Richmond, VA, USA



Everson, Greg 2013

Principles of kinetic measures
Greg Everson, MD, FACP
University of Colorado Denver, Denver, CO, USA

>Webcast (soon available)

 #03 - A real-world, observational cohort of patients with nonalcoholic fatty liver disease: The TARGET-NASH study
Miriam Vos, USA
 #04 - Novel multiparametric magnetic resonance elastography (MRE) protocol accurately predicts NAS score for NASH diagnosis
Alina Allen, USA
 #06 - Serum GP73 as a surrogate biomarker of significant liver fibrosis and cirrhosis in NAFLD
Fengmin Lu, China
 #07 - Plasma collagen type III (Pro-C3) levels associate with severity of histological features of non-alcoholic steatohepatitis and fibrosis within the screening population from the CENTAUR study
Diana Leeming, Denmark
  Session 6: Challenges Opportunities in integrating 'OMICS
  Chairs: Pierre Bedossa & Shadab Siddiqui

Schuck, Robert 2017 120

Big Data vs. the individual liver from a regulatory perspective
Robert Schuck, PharmD, PhD
FDA Center for Drug Evaluation and Research, Silver Spring, MD, USA



Mato, Jose 2017 120

Big Data vs. the individual liver from a developer's perspective
José María Mato de la Paz, PhD
CIC BioGUNE, Derio, Spain

>Presentation (not available)


Travison, Tom 120

Future scenarios of algorithm building
Tom Travison, PhD
Harvard Medical School & Hebrew SeniorLife Institute for Aging Research, Boston, MA, USA

>Webcast (not available)

 #08 - Next-Generation Sequencing (NGS) of two independent cohorts identifies eleven circulating miRNAs for diagnosis of NASH and fibrosis
Sven Francque, Belgium
 #09 - A new non-invasive diagnostic score to monitor change in disease activity and predict fibrosis evolution in patients with NASH
Dean Hum, France
>Presentation (soon available)
 #10 - A precision medicine approach to comprehensive NAFLD diagnosis via metabolomics-based liquid biopsy
Pablo Ortiz, Spain
  Session 7: The Liver in Context
Chairs: Veronica Miller & Arun Sanyal

Sanyal, Arun 2015_def

Integrated Assessment of diabetes, cardiovascular and liver risks and its potential application in the clinical management of NAFLD
Arun Sanyal, MD, MBBS
Virginia Commonwealth University, Richmond, VA, USA



Sninsky, John 2017 120

Navigating NASH biomarkers: From discovery to clinical practice
John Sninsky, PhD
CareDx, Brisbane, CA, USA





Program Committee

Organizing Committee